Eagle Pharmaceuticals has developed concentrated, low-viscosity liquid pharmaceutical formulations of proteins for rapid subcutaneous or intramuscular injection. The patent includes viscosity-reducing ionic liquids and antibodies, with an absolute viscosity of 1-100 cP at 25°C. GlobalData’s report on Eagle Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Eagle Pharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. Eagle Pharmaceuticals's grant share as of May 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11986526B2) discloses a liquid pharmaceutical formulation designed for injection, comprising an antibody, 4-ethyl-4-methylmorpholinium methylcarbonate (EMMC) or a salt thereof, and a pharmaceutically acceptable solvent. The formulation, with an absolute viscosity ranging from 1 cP to 100 cP at 25°C, demonstrates lower viscosity compared to a control composition lacking EMMC. The patent specifies the antibody's molecular weight, concentration, and the inclusion of various excipients like sugars, polymers, and stabilizing agents to enhance the formulation's properties.
Moreover, the patent details a method for administering the antibody through subcutaneous or intramuscular injection using the disclosed liquid pharmaceutical formulation. The injection process involves specific syringe types, including heated syringes, auto-injectors, or prefilled syringes, with the formulation being isotonic to human blood serum. The patent also highlights the formulation's reduced injection force requirements and primary irritation index, making it suitable for comfortable and effective administration. Additionally, a method for preparing the formulation by combining the antibody, solvent, and EMMC is outlined, along with a lyophilized composition that can be reconstituted to achieve the desired viscosity and antibody concentration post-reconstitution.
To know more about GlobalData’s detailed insights on Eagle Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
